Zai Lab Limited (Nasdaq: ZLAB; Hong Kong Stock Exchange: 9688), the commercial-stage biopharmaceutical company operating in China and the United States, announced on October 14, 2026, that it will present the first human clinical data for ZL-1503, its internally developed bispecific antibody targeting interleukin-13 and the interleukin-31 receptor alpha subunit. The findings will be disclosed at the American College of Allergy, Asthma & Immunology’s 2026 Annual Scientific Meeting, scheduled for November 12 through November 16 in Phoenix, Arizona. The presentation will focus on healthy volunteers participating in the single-ascending-dose portion of an ongoing Phase 1/1b trial.
ZL-1503 is designed to inhibit two biological pathways involved in atopic dermatitis and related inflammatory conditions. Interleukin-13 contributes to type 2 inflammation and skin barrier abnormalities, while interleukin-31 signaling is associated with itching and other inflammatory responses. Zai Lab believes that blocking both pathways through one long-acting antibody could provide broader disease control and potentially allow less frequent dosing than certain established treatments.
The upcoming presentation will include pharmacokinetic measurements, pharmacodynamic biomarkers, initial safety observations and immunogenicity information. However, Zai Lab has not disclosed the numerical human results in its October announcement, and the initial dataset concerns healthy volunteers rather than patients receiving treatment for eczema. The medicine’s ability to reduce clinical disease severity, improve itching or maintain remission has therefore not yet been demonstrated in humans.
The programme also includes a multiple-ascending-dose stage enrolling adults with moderate-to-severe atopic dermatitis. Zai Lab expects initial findings from that patient population during the first half of 2027. The development could eventually create an additional option in a competitive immunology market, but the immediate question is whether the antibody demonstrates appropriate target engagement and tolerability at exposures suitable for further clinical testing.
Why is Zai Lab targeting IL-13 and IL-31 signaling through one antibody?
Atopic dermatitis is a chronic inflammatory skin disorder characterized by recurrent eczema lesions, impaired skin barrier function and persistent itching. Disease severity varies considerably, but patients with moderate-to-severe symptoms may experience sleep disruption, discomfort and reduced quality of life. Treatment can be challenging because several biological pathways contribute to the condition.
Interleukin-13 is a key signaling molecule involved in type 2 inflammatory responses. Its activity can influence skin barrier integrity, immune-cell signaling and the persistence of inflammatory lesions. Medicines that inhibit IL-13 or related pathways have already demonstrated clinical efficacy in selected patients with atopic dermatitis.
Interleukin-31 has a different but overlapping role. It is particularly associated with the activation of itch-related sensory pathways and can contribute to inflammatory responses within the skin. Excessive itching may lead to repeated scratching, which damages the skin barrier and can intensify inflammation.
Zai Lab’s approach is intended to interfere with both mechanisms through a single molecular construct. By inhibiting IL-13 and IL-31 receptor alpha signaling simultaneously, the company hopes to address visible inflammation and itch-related symptoms within one treatment programme. This could be useful because symptom relief and improvements in skin lesions do not always occur at the same rate.
However, the two pathways are biologically interconnected, and their combined inhibition may not automatically produce additive clinical benefits. A treatment must demonstrate that its effects are meaningfully different from those achieved by inhibiting one pathway alone. The potential advantage of ZL-1503 therefore remains a clinical development hypothesis rather than a proven feature.
How does ZL-1503 differ from existing single-target eczema biologics?
ZL-1503 is a bispecific antibody, meaning it has been engineered to interact with two distinct therapeutic targets. Its molecular structure is designed to block IL-13 and the alpha subunit of the IL-31 receptor. The company has also incorporated modifications intended to extend the antibody’s circulating half-life.
Several established atopic dermatitis biologics already target related inflammatory pathways. Dupixent, containing dupilumab, blocks IL-4 receptor alpha and thereby inhibits signaling associated with both IL-4 and IL-13. Ebglyss, containing lebrikizumab, directly targets IL-13, while Nemluvio, containing nemolizumab, inhibits IL-31 receptor alpha.
These products establish clinical evidence that the two biological pathways are relevant to treatment. ZL-1503’s proposed differentiation involves combining the therapeutic targets of IL-13 inhibition and IL-31 receptor blockade in a single investigational antibody. However, combining known mechanisms does not establish that the resulting medicine is more effective than existing treatments.
The safety profile may also differ from those of single-target therapies. Inhibiting two pathways can influence immune signaling in ways that require careful assessment, particularly during repeated dosing. Established experience with individual antibodies cannot be used to guarantee the safety of a new bispecific construct.
Zai Lab has not announced a randomized head-to-head study comparing ZL-1503 with Dupixent, Ebglyss or Nemluvio. Its eventual competitive position will depend on clinical outcomes, dosing convenience, tolerability and reimbursement rather than the number of pathways included in its molecular design.
What did the earlier non-human primate studies reveal about ZL-1503?
Zai Lab presented preclinical findings during 2026 describing the biological activity of ZL-1503 in non-human primates. One investigation involved 16 cynomolgus monkeys allocated across four dose groups, including an untreated control. The evaluated doses were 0.3, 3 and 10 mg/kg, administered intravenously as a single treatment.
Researchers monitored IL-31-associated scratching behavior and IL-13-related STAT6 phosphorylation over a 112-day observation period. The findings showed dose-dependent effects on both the magnitude and duration of the biological response. Zai Lab also reported a relationship between measured drug exposure and pharmacodynamic activity.
A separate model of allergic airway disease involved nine non-human primates divided into three groups. The study examined respiratory and allergy-related measures after exposure to an experimental antigen challenge. ZL-1503 treatment was associated with improvements in airway resistance and dynamic compliance, alongside reductions in nasal rubbing and sneezing.
The reported differences were statistically significant for the measured airway and behavioral outcomes. However, each treatment group contained only three animals, limiting the precision and generalizability of the findings. The study also investigated experimental allergic disease rather than directly demonstrating improved eczema lesions in humans.
The 112-day observation period is relevant to the company’s interest in prolonged pharmacological activity. Nevertheless, observing pathway suppression over several months in animals does not establish the optimal dosing interval for patients. Human pharmacokinetic and safety data will be necessary before any claim of less frequent clinical dosing can be validated.
What will the November 13 first-in-human presentation establish?
Zai Lab’s ACAAI presentation is titled First-in-Human, Single Ascending Dose Study of ZL-1503, a Half-Life-Extended Anti-IL-13/IL-31Rα Bispecific Antibody, in Healthy Volunteers. It is scheduled for November 13 at 2:50 p.m. Mountain Time, with ePoster identification R376 and abstract number 8201. The company also plans an investor conference call on November 13 to discuss the findings and future development.
The presentation will examine how ZL-1503 behaves after administration at different dose levels. Pharmacokinetic measurements will help characterize exposure and the persistence of the antibody in circulation. This is important because the company’s proposed dosing convenience depends on whether sufficient drug levels can be maintained over an appropriate interval.
Pharmacodynamic measurements will assess whether the antibody influences the biological pathways it is designed to inhibit. Zai Lab has previously identified phosphorylated STAT6, commonly abbreviated pSTAT6, as a relevant biomarker of IL-13 signaling. Other exploratory markers may provide information about activity associated with the intended mechanism.
The first human safety and immunogenicity results will also be important. Immunogenicity refers to the potential for a biological medicine to trigger immune responses against the administered molecule, including the formation of antidrug antibodies. Such responses can influence drug exposure, tolerability or treatment activity.
However, healthy-volunteer biomarker changes cannot establish that patients will experience reduced itching or improved skin lesions. The initial study population does not have the same inflammatory disease characteristics as patients with moderate-to-severe atopic dermatitis. The November results should therefore be evaluated as early pharmacological evidence rather than a clinical efficacy readout.
How is the Phase 1/1b study designed to progress into patients with eczema?
The global trial, registered as NCT07235384, began in December 2025 and is designed as a randomized, double-blind, placebo-controlled Phase 1/1b study. It has an estimated enrollment of 84 participants across healthy-volunteer and atopic dermatitis cohorts. The programme includes clinical sites in Australia, China and the United States.
The investigation consists of two principal stages. Part A uses single ascending doses in healthy adults to assess initial safety, tolerability and pharmacokinetics. Part B evaluates multiple ascending doses in adults with moderate-to-severe atopic dermatitis, providing the opportunity to investigate repeated exposure and preliminary disease-related outcomes.
The single-dose stage enrolled healthy volunteers aged 18 to 65 years, with additional eligibility criteria designed to reduce confounding medical risks. This population allows investigators to examine drug behavior without the variability introduced by active inflammatory disease. However, healthy participants may respond differently from people with atopic dermatitis, particularly regarding pathway activation and baseline biomarker levels.
Zai Lab reported in August 2026 that enrollment had been completed in the single-ascending-dose portion. Recruitment continued in the multiple-dose patient cohorts. The company subsequently confirmed that the first human findings would be presented at ACAAI in November.
The multiple-dose stage is particularly important for determining whether the therapy produces clinically meaningful improvements. Unlike the healthy-volunteer phase, patients with atopic dermatitis can be evaluated for changes in disease severity, itching and related symptoms. However, the company has not yet released the corresponding patient efficacy results.
Why does extended antibody half-life matter for long-term eczema treatment?
Moderate-to-severe atopic dermatitis is a chronic condition that may require repeated treatment over many years. Patients and clinicians must balance effectiveness, safety, convenience and the burden of continuing injections or other medicines. A treatment that maintains adequate exposure over longer intervals could potentially reduce administration frequency.
Zai Lab engineered ZL-1503 with modifications intended to extend serum half-life. Its earlier financial disclosures identified YTE-related modifications as part of the molecular design. Such approaches are used in antibody engineering to influence interactions involved in antibody recycling and clearance.
However, longer circulation does not automatically mean better efficacy. A drug must remain present at sufficient concentrations to inhibit the intended pathways without causing unacceptable effects. The relevant duration also depends on the relationship between exposure and biological response.
Prolonged drug activity introduces additional safety considerations. If an unwanted immune-related effect occurs, the medicine’s biological activity may persist after administration stops. Appropriate dose selection and monitoring are therefore important when evaluating long-acting therapeutic antibodies.
The forthcoming pharmacokinetic results should help determine whether the molecular engineering performs as expected in humans. They may also inform the multiple-dose schedules used in patients. Zai Lab has not established an approved dosing interval or provided clinical evidence demonstrating greater convenience than existing eczema treatments.
How could dual inhibition change treatment outcomes in atopic dermatitis?
A major treatment objective in atopic dermatitis is reducing inflammation while improving symptoms that interfere with everyday life. Some patients experience substantial itching even when visible lesions improve, while others continue to have significant skin inflammation despite partial symptom relief. Targeting related but distinct pathways could theoretically address both problems.
ZL-1503’s design reflects this treatment challenge. IL-13 inhibition is intended to address inflammatory signaling, while IL-31 receptor blockade is intended to influence itch-related responses. If the two mechanisms operate effectively together, the molecule may produce a broader pattern of improvement.
Nevertheless, the clinical importance of such an approach depends on the size, speed and durability of treatment effects. A bispecific antibody would need to demonstrate meaningful outcomes on validated measures such as the Eczema Area and Severity Index, Investigator’s Global Assessment and itch severity scores. The October announcement does not provide results on any of these clinical endpoints.
Treatment comparisons also require attention to background therapy and patient characteristics. Individuals with moderate-to-severe atopic dermatitis may have received topical corticosteroids, systemic immunomodulators or previous biological treatments. Their response to a new medicine can depend on disease history and existing treatment resistance.
The future patient cohort may provide initial signals relevant to these questions. However, a small Phase 1b population would not normally establish definitive superiority over approved medicines or support broad conclusions about long-term disease control. Larger randomized studies would be required if early results justify further development.
What does ZL-1503 contribute to Zai Lab’s broader business strategy?
Zai Lab has been expanding beyond its earlier business model centered largely on commercializing licensed therapies in China. Its current strategy includes developing internally discovered medicines for global markets, particularly in oncology and immunology. ZL-1503 represents one of the company’s internally generated biological programmes.
The company reported total second-quarter 2026 revenue of $106.3 million, compared with $110 million in the corresponding period of 2025. Net product revenue increased 11% sequentially, supported partly by demand for established medicines including VYVGART. The company reported a quarterly net loss of $50.8 million while continuing to invest in research and development.
At June 30, Zai Lab held approximately $717.5 million in cash, short-term investments and current restricted cash combined. The total includes restricted funds and should not be treated as entirely unrestricted liquidity. The balance provides financial context for continued investment across its internal and partnered development programmes.
ZL-1503 is part of a growing pipeline that also includes oncology assets and immunology medicines being developed through external partnerships. Its potential importance lies in giving Zai Lab greater ownership of a new molecule rather than relying exclusively on regional commercialization rights for another company’s discovery.
However, the commercial contribution remains speculative. ZL-1503 is still in early human testing and has not generated product revenue. The company has not disclosed an approved indication, launch date or reliable sales forecast.
What must the first human data demonstrate before ZL-1503 can advance?
The first development requirement is an acceptable safety and tolerability profile across the investigated dose levels. Researchers must also establish how exposure changes with dose and whether the antibody produces measurable inhibition of its intended pathways. These findings will influence selection of suitable regimens for repeated administration.
The next stage must determine whether pathway inhibition translates into clinical improvements among patients with active atopic dermatitis. Reductions in validated itch scores, eczema severity and disease-related quality-of-life measures will be important. Investigators will also need to assess whether the treatment’s effects persist across the intended dosing interval.
Safety during repeated administration will be another consideration. Antidrug antibodies, hypersensitivity reactions and other treatment-emergent effects may become more apparent after multiple doses. Long-term development will need to establish whether simultaneous IL-13 and IL-31 receptor inhibition maintains an acceptable benefit-risk profile.
The company expects initial patient data from the multiple-ascending-dose part of the trial during the first half of 2027. Those findings will be more informative about potential eczema efficacy than the November healthy-volunteer presentation. Their interpretation will nevertheless depend on patient numbers, follow-up and the role of placebo comparisons.
Zai Lab’s upcoming ACAAI presentation marks an important transition for ZL-1503 from preclinical research to publicly disclosed human pharmacology. Its molecular design offers a plausible strategy for addressing both inflammation and itching through one antibody, supported by earlier animal evidence of sustained pathway inhibition. The central question is whether that activity can be reproduced safely in patients and converted into clinically meaningful relief.
Until patient efficacy results become available, ZL-1503 remains an investigational bispecific antibody with an unproven advantage over established atopic dermatitis treatments. The November 13 findings will provide an early assessment of human exposure and target engagement, while the subsequent patient cohort will determine whether the mechanism merits more advanced clinical development.
